In this thread we discuss hypothetical substances. and if they are even possible to make.

To start this off i introduce to you:
>HEXATRYPHEX

A theoretical psychedelic that fuses multiple psychotropic domains into one ultra-potent, ultra-complex molecule.

The core concept:
>An ergoline nucleus (like LSD)
>A phenethylamine tail (like 2C-T-7)
>A tryptamine moiety (like psilocin)
>A rigidified tricyclic bridge (like TCAs)
>And an allosteric NMDA modulator arm (like ketamine analogs)
>All in one single molecule, with multiple rotatable or locked binding conformations.

Dosage ~ 2–5 micrograms (super-agonist binding efficiency)
Duration Estimated 120–200+ hours

>Polypharmacology
Hits: "5-HT2A" + "5-HT1A" + "D2" + "TAAR1" + "NMDA (mod)" + "sigma-1" + "H1".

>Hybrid scaffold
Fused lysergamide–phenethyl–tryptamine core
Dual-side chains; One polar (amine-based), one lipophilic (aryl)

>Rotational locking
Tricyclic moiety forces rigid conformation, increasing potency.

The molecule would be very hard to synthesize.
it would have massive (~700–900 Da) but still pass BBB, Impossible to titrate safely — a few micrograms could get you a full psychedelic overload. It would be active at multiple receptor types simultaneously and a probable nightmare for metabolism, lingering in fat stores for weeks.

>>16699079 (OP)
This doesn't really make sense. Ergolines contain within them the tryptamine and phenethylamine structure already, it is also already more than tricyclic. So the only thing left is 5-HT2A with NMDA antagonist activity. It is conceivable to tether them together as in MDAN-21.

You can't just glue functional groups together and expect to get anything. A group beneficial in one ligand will be detrimental in another one because the second ligand positions itself slightly differently in the orthosteric pocket. Making a compound more rigid can lock the active conformation or take the required flexibility for effective binding.

>uses em dash
AI slop